Does Retrovir (zidovudine) cause side effects?
Retrovir IV Infusion (zidovudine [ZDV] - formerly called azidothymidine [AZT]) is a type of antiviral medication called a pyrimidine nucleoside analogue used to treat human immunodeficiency virus (HIV) and to prevent HIV transmission from an infected mother to her fetus.
Common side effects of Retrovir include
- chills,
- rash,
- confusion,
- dizziness,
- severe headache,
- diarrhea,
- weakness,
- pain,
- insomnia,
- nausea, and
- weight loss.
Serious side effects of Retrovir include
- a decrease in blood cells,
- muscle pain,
- enlarged liver (hepatomegaly),
- metabolic disturbance (lactic acidosis), and
- liver toxicity, including neutropenia and severe anemia, particularly in patients with advanced human immunodeficiency virus (HIV) disease.
Drug interactions of Retrovir include fluconazole, probenecid, and trimethoprim, which reduce the elimination of Retrovir and therefore increase the blood concentration of Retrovir which can lead to increased side effects from Retrovir.
Retrovir is used to prevent transmission of the HIV virus from mother to fetus. Although it is unknown if Retrovir passes into breast milk, HIV infected mothers should not breastfeed because of the potential risk of transmitting HIV to an infant.
What are the important side effects of Retrovir (zidovudine)?
WARNING
Retrovir (zidovudine) has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced human immunodeficiency virus (HIV) disease.
Prolonged use of Retrovir has been associated with symptomatic myopathy.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including Retrovir and other antiretrovirals.
The most severe side effects of ziovudine are
- a decrease in blood cells,
- muscle pain (myopathy),
- enlarged liver,
- (hepatomegaly),
- and metabolic disturbance (lactic acidosis).
Other side effects are
Retrovir (zidovudine) side effects list for healthcare professionals
The following adverse reactions are discussed in greater detail in other sections of the labeling:
- Hematologic toxicity, including neutropenia and anemia.
- Symptomatic myopathy.
- Lactic acidosis and severe hepatomegaly with steatosis.
- Hepatic decompensation in patients co-infected with HIV-1 and hepatitis C.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults
The frequency and severity of adverse reactions associated with the use of Retrovir are greater in patients with more advanced infection at the time of initiation of therapy.
Table 3 summarizes adverse reactions reported at a statistically significant greater incidence for subjects receiving oral Retrovir in a monotherapy trial.
Table 3. Percentage (%) of Subjects with Adverse Reactions (Greater than or Equal to 5% Frequency) in Asymptomatic HIV-1 Infection (ACTG 019)
Adverse Reaction | Retrovir 500 mg/day (n = 453) | Placebo (n = 428) |
Body as a whole | ||
Asthenia | 9% a | 6% |
Headache | 63% | 53% |
Malaise | 53% | 45% |
Gastrointestinal | ||
Anorexia | 20% | 11% |
Constipation | 6% a | 4% |
Nausea | 51% | 30% |
Vomiting | 17% | 10% |
a Not statistically significant versus placebo. |
In addition to the adverse reactions listed in Table 3, adverse reactions observed at an incidence of greater than or equal to 5% in any treatment arm in clinical trials (NUCA3001, NUCA3002, NUCB3001, and NUCB3002) were
- abdominal cramps,
- abdominal pain,
- arthralgia,
- chills,
- dyspepsia,
- fatigue,
- insomnia,
- musculoskeletal pain,
- myalgia, and
- neuropathy.
Additionally, in these trials hyperbilirubinemia was reported at an incidence of less than or equal to 0.8%.
Selected laboratory abnormalities observed during a clinical trial of monotherapy with oral Retrovir are shown in Table 4.
Table 4. Frequencies of Selected (Grade 3/4) Laboratory Abnormalities in Subjects with Asymptomatic HIV-1 Infection (ACTG 019)
Test (Abnormal Level) | Retrovir 500 mg/day (n = 453) | Placebo (n = 428) |
Anemia (Hgb <8 g/dL) | 1% | <1% |
Granulocytopenia (<750 cells/mm3) | 2% | 2% |
Thrombocytopenia (platelets <50,000/mm3) | 0% | <1% |
ALT (>5 x ULN) | 3% | 3% |
AST (>5 x ULN) | 1% | 2% |
ULN = Upper limit of normal. |
The adverse reactions reported during IV administration of Retrovir injection are similar to those reported with oral administration; neutropenia and anemia were reported most frequently. Long-term IV administration beyond 2 to 4 weeks has not been studied in adults and may enhance hematologic adverse reactions. Local reaction, pain, and slight irritation during IV administration occur infrequently.
Pediatrics
The clinical adverse reactions reported among adult recipients of Retrovir may also occur in pediatric patients.
Trial ACTG 300
Selected clinical adverse reactions and physical findings with a greater than or equal to 5% frequency during therapy with Epivir (lamivudine) oral suspension 4 mg per kg twice daily plus Retrovir 160 mg per m2 3 times daily compared with didanosine in therapy-naive (less than or equal to 56 days of antiretroviral therapy) pediatric subjects are listed in Table 5.
Table 5. Selected Clinical Adverse Reactions and Physical Findings (Greater than or Equal to 5% Frequency) in Pediatric Subjects in Trial ACTG 300
Adverse Reaction | Epivir plus Retrovir (n = 236) | Didanosine (n = 235) |
Body as a whole | ||
Fever | 25% | 32% |
Digestive | ||
Hepatomegaly | 11% | 11% |
Nausea & vomiting | 8% | 7% |
Diarrhea | 8% | 6% |
Stomatitis | 6% | 12% |
Splenomegaly | 5% | 8% |
Respiratory | ||
Cough | 15% | 18% |
Abnormal breath sounds/wheezing | 7% | 9% |
Ear, Nose, and Throat | ||
Signs or symptoms of earsa | 7% | 6% |
Nasal discharge or congestion | 8% | 11% |
Other | ||
Skin rashes | 12% | 14% |
Lymphadenopathy | 9% | 11% |
a Includes pain, discharge, erythema, or swelling of an ear. |
Selected laboratory abnormalities experienced by therapy-naive (less than or equal to 56 days of antiretroviral therapy) pediatric subjects are listed in Table 6.
Table 6. Frequencies of Selected (Grade 3/4) Laboratory Abnormalities in Pediatric Subjects in Trial ACTG 300
Test (Abnormal Level) | Epivir plus Retrovir | Didanosine |
Neutropenia (ANC <400 cells/mm3) | 8% | 3% |
Anemia (Hgb <7.0 g/dL) | 4% | 2% |
Thrombocytopenia (platelets <50,000/mm3) | 1% | 3% |
ALT (>10 x ULN) | 1% | 3% |
AST (>10 x ULN) | 2% | 4% |
Lipase (>2.5 x ULN) | 3% | 3% |
Total amylase (>2.5 x ULN) | 3% | 3% |
ULN = Upper limit of normal. ANC = Absolute neutrophil count. |
Macrocytosis was reported in the majority of pediatric subjects receiving Retrovir 180 mg per m2 every 6 hours in open-label trials. Additionally, adverse reactions reported at an incidence of less than 6% in these trials were
- congestive heart failure,
- decreased reflexes,
- ECG abnormality,
- edema,
- hematuria,
- left ventricular dilation,
- nervousness/irritability, and
- weight loss.
Use For The Prevention Of Maternal-Fetal Transmission Of HIV-1
In a randomized, double-blind, placebo-controlled trial in HIV-1-infected women and their neonates conducted to determine the utility of Retrovir for the prevention of maternal-fetal HIV-1 transmission, Retrovir syrup at 2 mg per kg was administered every 6 hours for 6 weeks to neonates beginning within 12 hours following birth.
- The most commonly reported adverse reactions were anemia (hemoglobin less than 9.0 g per dL) and neutropenia (less than 1,000 cells per mm3).
- Anemia occurred in 22% of the neonates who received Retrovir and in 12% of the neonates who received placebo.
- The mean difference in hemoglobin values was less than 1.0 g per dL for neonates receiving Retrovir compared with neonates receiving placebo.
- No neonates with anemia required transfusion and all hemoglobin values spontaneously returned to normal within 6 weeks after completion of therapy with Retrovir.
- Neutropenia in neonates was reported with similar frequency in the group that received Retrovir (21%) and in the group that received placebo (27%). The long-term consequences of in utero and infant exposure to Retrovir are unknown.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Retrovir. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Body As A Whole
Back pain, chest pain, flu-like syndrome, generalized pain, redistribution/accumulation of body fat.
Cardiovascular
Eye
Macular edema.
Gastrointestinal
Constipation, dysphagia, flatulence, oral mucosa pigmentation, mouth ulcer.
General
Sensitization reactions including anaphylaxis and angioedema, vasculitis.
Hematologic
Aplastic anemia, hemolytic anemia, leukopenia, lymphadenopathy, pancytopenia with marrow hypoplasia, pure red cell aplasia.
Hepatobiliary
Hepatitis, hepatomegaly with steatosis, jaundice, lactic acidosis, pancreatitis.
Musculoskeletal
Increased CPK, increased LDH, muscle spasm, myopathy and myositis with pathological changes (similar to that produced by HIV-1 disease), rhabdomyolysis, tremor.
Nervous
Anxiety, confusion, depression, dizziness, loss of mental acuity, mania, paresthesia, seizures, somnolence, vertigo.
Reproductive System And Breast
Respiratory
Skin And Subcutaneous Tissue
Changes in skin and nail pigmentation, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, sweating, urticaria.
Special Senses
Amblyopia, hearing loss, photophobia, taste perversion.
Renal And Urinary
Urinary frequency, urinary hesitancy.
What drugs interact with Retrovir (zidovudine)?
Antiretroviral Agents
Stavudine
Concomitant use of zidovudine with stavudine should be avoided since an antagonistic relationship has been demonstrated in vitro.
Nucleoside Analogues Affecting DNA Replication
Some nucleoside analogues affecting DNA replication, such as ribavirin, antagonize the in vitro antiviral activity of Retrovir against HIV-1; concomitant use of such drugs should be avoided.
Doxorubicin
Concomitant use of zidovudine with doxorubicin should be avoided since an antagonistic relationship has been demonstrated in vitro.
Hematologic/Bone Marrow Suppressive/Cytotoxic Agents
Coadministration of ganciclovir, interferon alfa, ribavirin, and other bone marrow suppressive or cytotoxic agents may increase the hematologic toxicity of zidovudine.
Summary
Retrovir IV Infusion (zidovudine [ZDV]) is a type of antiviral medication called a pyrimidine nucleoside analogue used to treat human immunodeficiency virus (HIV) and to prevent HIV transmission from an infected mother to her fetus. Common side effects of Retrovir include chills, rash, confusion, dizziness, severe headache, diarrhea, weakness, pain, insomnia, nausea, and weight loss. Retrovir is used to prevent transmission of the HIV virus from mother to fetus. Although it is unknown if Retrovir passes into breast milk, HIV infected mothers should not breastfeed because of the potential risk of transmitting HIV to an infant.
Multimedia: Slideshows, Images & Quizzes
-
What Are HIV & AIDS? Symptoms, Treatment, and Prevention
HIV, or human immunodeficiency virus, causes acquired immunodeficiency syndrome, or AIDS. Learn about HIV symptoms, HIV test, HIV...
-
HIV AIDS: Myths and Facts
What is HIV versus AIDS? What are the symptoms of HIV? Is there an HIV cure? Discover myths and facts about living with HIV/AIDS....
-
A Timeline of the HIV/AIDS Pandemic
Get a historical overview of the HIV/AIDS pandemic from human contraction to the present through this slideshow of pictures.
-
Picture of HIV Lipodystrophy
HIV lipodystrophy describes a constellation of changes in subcutaneous and visceral fat distribution in patients on...
-
HIV & AIDS Quiz: HIV Testing & Symptoms
Now, more than ever, you should know about HIV/AIDS, especially its causes, symptoms treatments, and complications. Take the...
-
Picture of HIV/AIDS
Acronym for the Human Immunodeficiency Virus, the cause of AIDS (acquired immunodeficiency syndrome). See a picture of HIV/AIDS...
-
Picture of HIV-associated Dementia (HAD)
A 40-year-old woman diagnosed with HIV presented with confusion and decline in memory. See a picture of HIV-associated Dementia...
Related Disease Conditions
-
HIV Early Signs and Stages
HIV (human immunodeficiency virus) weakens your immune system. Some people with HIV don’t have any symptoms, but those that do may experience mononucleosis-like or flu-like symptoms. There are 3 stages of HIV.
-
HIV and AIDS
Second Source article from WebMD
-
Human Immunodeficiency Virus (HIV)
HIV (human immunodeficiency virus) infection left untreated causes AIDS (acquired immunodeficiency syndrome). The human immunodeficiency virus (HIV) is a type of virus called a retrovirus, which can infect humans when it comes in contact with tissues that line the vagina, anal area, mouth, or eyes, or through a break in the skin. HIV infection is generally a slowly progressive disease in which the virus is present throughout the body at all stages of the disease. Three stages of HIV infection have been described. The initial stage of infection (primary infection), which occurs within weeks of acquiring the virus, often is characterized by the flu- or mono-like illness that generally resolves within weeks. The stage of chronic asymptomatic infection (meaning a long duration of infection without symptoms) lasts an average of eight to 10 years without treatment. The stage of symptomatic infection, in which the body's immune (or defense) system has been suppressed and complications have developed, is called the acquired immunodeficiency syndrome (AIDS). The symptoms are caused by the complications of AIDS, which include one or more unusual infections or cancers, severe loss of weight, and intellectual deterioration (called dementia). When HIV grows (that is, by reproducing itself), it acquires the ability to change (mutate) its own structure. These mutations enable the virus to become resistant to previously effective drug therapy. The goals of drug therapy are to prevent damage to the immune system by the HIV virus and to halt or delay the progress of the infection to symptomatic disease. Therapy for HIV includes combinations of drugs that decrease the growth of the virus to such an extent that the treatment prevents or markedly delays the development of viral resistance to the drugs. The best combination of drugs for HIV are those that effectively suppress viral replication in the blood and also are well tolerated and simple to take so that people can take the medications consistently without missing doses.
-
AIDS (Acquired Immunodeficiency Syndrome)
AIDS is the advanced stage of HIV infection. Symptoms and signs of AIDS include pneumonia due to Pneumocystis jiroveci, tuberculosis, toxoplasmosis, seizures, weakness, meningitis, yeast infection of the esophagus, and Kaposi's sarcoma. Anti-retroviral therapy (HAART) is used in the treatment of AIDS.
-
HIV vs. AIDS
Human immunodeficiency virus causes HIV infection. Acquired immunodeficiency syndrome (AIDS) is a condition that results after HIV has extensively damaged a person's immune system. Risk factors for HIV and AIDS include use of contaminated needles or syringes, unprotected sex, STDs, receiving a blood transfusion prior to 1985 in the United States, having many sex partners, and transmission from a mother to her child.
-
HIV Medications List and Drug Charts
The ultimate goal of HIV treatment is getting the viral load down below detectable levels. As long as those viral load and antibody levels are below a proscribed range, people with HIV can stave off AIDS and other serious symptoms. Antiviral treatment options usually include combinations of two NRTIs, often referred to as "nucs," and a third drug, typically being a boosted protease inhibitor, a NNRTI, often called "non-nucs," and integrase strand transfer inhibitors.
-
HIV/AIDS Infection Transmission and Prevention
HIV (human immunodeficiency virus) is spread through contact with genital fluids or blood of an infected person. The spread of HIV can occur when these secretions come in contact with tissues such as those lining the vagina, anal area, mouth, eyes (the mucus membranes), or with a break in the skin, such as from a cut or puncture by a needle.
-
HIV/AIDS Testing: Diagnosis and Monitoring
HIV/AIDS diagnosis and monitoring have come a long way from the days when a diagnosis was a death sentence. Crucial parts of the effective treatment regimens developed in the last 40 years are consistent monitoring of the viral load (the amount of virus in the blood), and the immune cell count, which function as biological markers of the disease’s progression. Doctors also must test for drug resistance.
-
HIV/AIDS Facts: What Is HIV?
HIV (human immunodeficiency virus) is the precursor infection to AIDS (acquired immunodeficiency syndrome). HIV is transmitted through blood and genital secretions; most people get it through sexual contact or sharing needles for illegal IV drug use. HIV can be controlled by a strict drug regimen, but left unchecked, it leads to AIDS. In AIDS, the immune system collapses and the body falls prey to secondary, opportunistic infections and cancers that typically kill the person.
-
What Are the Side Effects of HIV Medications?
It’s important to know the potential side effects of all the drugs you take to control your HIV infection, as well as potential drug interactions. All of the NNRTIs (nonnucleoside analogue reverse transcriptase inhibitors), for example, are associated with important drug-drug interactions so they must be used with caution in patients on other medications. Learn more about the side effects of the drugs in standard treatment regimens.
-
When should you start HIV medication?
Nearly everyone who is infected with HIV (human immunodeficiency virus) should start antiviral medication therapy as soon as they are diagnosed. Older guidelines recommended delaying treatment to help reduce the potential for drug side effects and viral resistance to treatment. Current thinking theorizes that early treatment may preserve more of the body's immune function.
Treatment & Diagnosis
- HIV-AIDS FAQs
- HIV Treatment, Medications, and Prevention
- HIV: Two Patients Face The Diagnosis
- HIV Treatment - To Interrupt or Not
- Unprotected Sex Between HIV-Infected Partners: What's the Harm?
- HIV Urine Test Approved
- HIV Transmission and Progression to AIDS Continues
- Babies On The Breast Of HIV Moms
- Does Circumcision Prevent HIV and AIDS?
- Can HIV Cause Kaposi's Sarcoma?
- Do You Need Antiretroviral Therapy for HIV with No Symptoms?
- Does HIV Cause Colorectal Cancer?
- Does Anti-Retroviral Therapy for HIV Cause Diabetes?
- How Long Should You Wait to Get an HIV Test?
- What Liver Problems Does HIV Cause?
- HIV Infection Facts, History, Causes, and Risk Factors
- HIV Tests, Symptoms, Signs, and Stages of Infection
- Baby "Cured" of HIV Infection
Medications & Supplements

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.